Clinical trials: Marginal Zone B-Cell Lymphoma
Lymphoplasmacytic Lymphoma, Waldenstrom Macroglobulinemia
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
This phase II trial studies the effects of venetoclax and rituximab in comparison to ibrutinib and rituximab or zanubrutinib in treating patients with previously untreated Waldenstrom's macroglobulinemia/lymphoplasmacytic…
- Trial name
- NCT04840602
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
- Where
- 150 sites in United States
- Volunteers
- 92 people
- Sponsor
- National Cancer Institute (NCI)
Non-Hodgkin Lymphoma
A Clinico-Pathological Study to Investigate the Possible Infective Causes of Non-Hodgkin Lymphoma of the Ocular Adnexae
Patients with mucosa-associated lymphoid tissue (MALT) lymphoma of the ocular adnexae (MLOA) will be eligible for treatment with doxycycline (part A: clinico-pathological study); patients with other types of ocular lymphoma…
- Trial name
- IELSG27 (NCT01010295)
- Testing
- doxycycline (tetracycline)
- Where
- 6 sites in Chile, Italy and 2 more
- Volunteers
- 54 people
- Sponsor
- International Extranodal Lymphoma Study Group (IELSG)
Follicular Lymphoma, Marginal Zone Lymphoma
Velcade, Nipent, Rituxan (VNR) in Subjects With Relapsed Follicular, Marginal Zone, and Mantle Cell Lymphoma
This is a phase 1/2 Study of VELCADE (bortezomib), Nipent (pentostatin), and Rituxan (rituximab) (VNR) in Subjects with Relapsed Follicular, Marginal Zone, and Mantle Cell Lymphoma.
- Conditions
- Follicular Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma
- Trial name
- NCT01460602
- Testing
- MTD of Velcade, Nipent and Rituxan established in Part 1
- Where
- United States
- Sponsor
- Louisiana State University Health Sciences Center Shreveport
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant
This randomized phase I trial studies the side effects of vaccine therapy in preventing cytomegalovirus (CMV) infection in patients with hematological malignancies undergoing donor stem cell transplant.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Trial name
- NCT01588015
- Testing
- tetanus-CMV fusion peptide vaccine, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- City of Hope Medical Center
B-Cell Non-Hodgkin Lymphoma, Large B Cell Diffuse Lymphoma
JWCAR239 in Patients With B Cell Non-Hodgkin Lymphoma
JWCAR239 is a CD19/CD20 CAR-T product. This trial is intended to evaluate the safety, PK/PD and efficacy of JWCAR239 in patients with B Cell Non-Hodgkin Lymphoma (B-NHL)
- Conditions
- B-Cell Non-Hodgkin Lymphoma, Large B Cell Diffuse Lymphoma, Follicular Lymphoma, Marginal Zone B Cell Lymphoma
- Trial name
- NCT07024147
- Testing
- JWCAR239, Fludarabine, Cyclophosphamide
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Peking University Cancer Hospital & Institute
Lymphoma
Busulfan, Melphalan, and Thiotepa in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Hodgkin's or Non-Hodgkin's Lymphoma
RATIONALE: Chemotherapy, such as busulfan, melphalan, and thiotepa, may destroy cancerous blood-forming cells (stem cells) in the blood and bone marrow.
- Trial name
- NCT00238433
- Testing
- filgrastim, busulfan, melphalan
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- OHSU Knight Cancer Institute
Non-Hodgkin Lymphoma, Grade 1 Follicular Lymphoma
Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma
This phase II trial tests the effects of mosunetuzumab with or without polatuzumab vedotin and obinutuzumab for the treatment of patients with indolent B-cell non-Hodgkin lymphoma.
- Conditions
- Non-Hodgkin Lymphoma, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma
- Trial name
- NCT05169658
- Testing
- Mosunetuzumab, Obinutuzumab, Polatuzumab Vedotin
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- University of Washington
Hairy Cell Leukemia, Splenic Marginal Zone Lymphoma
Assessment of the V600E Mutation in the B-RAF Gene in Chronic Lymphoproliferative Disease
The presence of a specific mutation in the gene known as B-RAF has been found in patients who have Hairy Cell Leukemia. In this study this specific mutation known as V600E will be ascertained in peripheral blood samples of…
- Trial name
- B-RAF V600E (NCT01720758)
- Volunteers
- 20 people
- Sponsor
- HaEmek Medical Center, Israel
Adult Nasal Type Extranodal NK/T-Cell Lymphoma, Adult T-Cell Leukemia/Lymphoma
Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma
This pilot clinical trial studies Salvia hispanica seed in reducing the risk of returning disease (recurrence) in patients with non-Hodgkin lymphoma.
- Conditions
- Adult Nasal Type Extranodal NK/T-Cell Lymphoma, Adult T-Cell Leukemia/Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-Cell Lymphoma
- Trial name
- NCT02652715
- Testing
- Laboratory Biomarker Analysis, Quality-of-Life Assessment, Questionnaire Administration
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Mayo Clinic
Lymphoma, Large B-Cell, Diffuse, Follicular Lymphoma
Lenalidomide and R-CHOP in B-cell Lymphoma
The purpose of the study is to determine the recommended dose (RD) of lenalidomide (Revlimid) when administered in association with R-CHOP (rituximab (R), cyclophosphamide, doxorubicin, vincristine and prednisone).
- Conditions
- Lymphoma, Large B-Cell, Diffuse, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma
- Trial name
- R2CHOP-1 (NCT00901615)
- Testing
- Lenalidomide and R-CHOP
- Where
- 5 sites in France
- Volunteers
- 108 people
- Sponsor
- Lymphoma Study Association
Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma
Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies
This phase I trial studies the side effects and best dose of monoclonal antibody therapy before stem cell transplant in treating patients with relapsed or refractory lymphoid malignancies.
- Conditions
- Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma
- Trial name
- NCT01678443
- Testing
- indium In 111 anti-CD45 monoclonal antibody BC8, yttrium Y 90 anti-CD45 monoclonal antibody BC8, peripheral blood stem cell transplantation
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Fred Hutchinson Cancer Center
Non-Hodgkin Lymphoma
Copanlisib in Combination With Venetoclax in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma.
A significant number of patients with non-Hodgkin lymphoma (NHL) are not cured with available treatments and will eventually relapse.
- Trial name
- NCT03886649
- Testing
- Copanlisib, Venetoclax
- Where
- 6 sites in Switzerland
- Volunteers
- 7 people
- Sponsor
- Swiss Cancer Institute
MALT Lymphoma
Thalidomide in Mucosa Associated Lymphoid Tissue (MALT) Lymphoma Patients
The purpose of this study is to evaluate Thalidomide for treatment of disseminated MALT Lymphoma or at relapse following helicobacter pylori (HP) - eradication or chemotherapy or radiation.
- Trial name
- NCT00373646
- Testing
- Thalidomide, Pharmion
- Where
- Austria
- Volunteers
- 8 people
- Sponsor
- Medical University of Vienna
Adult Acute Lymphoblastic Leukemia in Remission, Adult B Acute Lymphoblastic Leukemia
Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery
This phase I trial studies the side effects and best dose of dasatinib in treating patients with solid tumors or lymphomas that are metastatic or cannot be removed by surgery.
- Conditions
- Adult Acute Lymphoblastic Leukemia in Remission, Adult B Acute Lymphoblastic Leukemia, Adult Hepatocellular Carcinoma, Adult Nasal Type Extranodal NK/T-Cell Lymphoma
- Trial name
- NCT00608361
- Testing
- Dasatinib, Pharmacological Study
- Where
- 23 sites in United States
- Volunteers
- 80 people
- Sponsor
- National Cancer Institute (NCI)
Cancer Survivor, Chronic Myeloproliferative Disorders
Presence of Donor-Derived DNA in Semen Samples From Cancer Survivors Who Underwent Donor Stem Cell Transplant
RATIONALE: Studying samples of semen from cancer survivors in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Conditions
- Cancer Survivor, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma
- Trial name
- NCT01077440
- Testing
- DNA analysis, polymerase chain reaction, flow cytometry
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Vanderbilt University
Lymphoma
Linperlisib Combination With Obinutuzumab Frontline Treatment of Marginal Zone Lymphoma Patients (MZL)
This is a single arm, open label, national multicenter clinical study included patients with marginal zone lymphoma patients (MZL) , aim is to evaluate the efficacy and safety of first-line treatment with Linperlisib combined…
- Trial name
- MZL-001 (NCT06592170)
- Testing
- Linperlisib combination with obinutuzumab
- Where
- China
- Volunteers
- 35 people
- Sponsor
- The First Hospital of Jilin University
Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma
A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001)
The purpose of this study is to evaluate the safety, pharmacokinetics, immunogenicity, and efficacy of zilovertamab vedotin given intravenously (IV) across a range of dose levels in participants with previously treated…
- Conditions
- Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma
- Trial name
- NCT03833180
- Testing
- Zilovertamab vedotin
- Where
- 14 sites in United States
- Volunteers
- 91 people
- Sponsor
- VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Brain and Central Nervous System Tumors, Extragonadal Germ Cell Tumor
Melphalan in Patients With Neoplastic Meningitis
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of melphalan in patients with persistent or recurrent…
- Conditions
- Brain and Central Nervous System Tumors, Extragonadal Germ Cell Tumor, Leukemia, Lymphoma
- Trial name
- NCT00002750
- Testing
- melphalan
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Duke University
Chronic Myeloproliferative Disorders, Leukemia
A Standardized Nursing Intervention Protocol for HCT Patients
RATIONALE: Visiting patients at home to teach them about self care after a stem cell transplant may be more effective than standard therapy in improving quality of life.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00951626
- Testing
- exercise intervention, telephone-based intervention, dietary intervention
- Where
- United States
- Volunteers
- 282 people
- Sponsor
- City of Hope Medical Center
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders
3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
RATIONALE: Diagnostic procedures, such as 3'-deoxy-3'-[18F] fluorothymidine (FLT) PET imaging, may help find and diagnose cancer.
- Conditions
- Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma
- Trial name
- NCT00935090
- Testing
- 3'-deoxy-3'-[18F]fluorothymidine
- Where
- United States
- Sponsor
- Barbara Ann Karmanos Cancer Institute